ALEXANDRIA, Va., June 18 -- United States Patent no. 12,325,749, issued on June 10, was assigned to Beijing Sinotau Bio-Pharmaceuticals Technology Co. Ltd. (Beijing).
"Anti-PD-L1 antibody and use thereof" was invented by Tong Zhou (Birmingham, Ala.), Fengqi Cao (Beijing), Zhe Li (Beijing) and Xiuli Jin (Beijing).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is an isolated antibody or antigen-binding fragment thereof that binds specifically to human CD-L1 protein, a nucleic acid molecule encoding the same, therapeutic compositions thereof, and their use to treat a PD-L1 related disease, such as a tumor which is PD-L1 positive."
The patent was filed on July 19, 2019, under Application No. 17/628,536....